When a Rare Peptide-Secreting Tumor Caused Unexpected Heart Valve Damage
A rare VIP-secreting tumor was found to cause the same type of heart valve damage usually seen only with classical carcinoid tumors.
Quick Facts
What This Study Found
A patient with previously undiagnosed VIPoma was found to have tricuspid regurgitation and stenosis on echocardiography — cardiac valve changes typically associated with classical carcinoid syndrome but not historically seen with VIP-secreting tumors. The echocardiographic finding of carcinoid heart disease prompted the workup that ultimately led to the VIPoma diagnosis.
This is notable because VIPomas have an incidence of only 0.05%–2% of neuroendocrine tumors, and cardiac valve involvement has not been a recognized feature of these tumors. The case suggests that the spectrum of neuroendocrine tumors capable of causing carcinoid heart disease may be wider than previously understood.
Key Numbers
VIPoma incidence: 0.05%–2% of neuroendocrine tumors
How They Did This
Single patient case report published in BMJ Case Reports. The authors describe a patient whose echocardiogram revealed tricuspid regurgitation and stenosis, which prompted further investigation and ultimately led to the diagnosis of a VIP-secreting tumor.
Why This Research Matters
This case challenges the assumption that only serotonin-secreting carcinoid tumors cause heart valve damage. If VIPomas can also produce carcinoid heart changes, clinicians may need to broaden their diagnostic thinking when they encounter unexplained tricuspid valve disease — potentially catching rare neuroendocrine tumors earlier.
The Bigger Picture
Neuroendocrine tumors release various peptide hormones into the bloodstream, and different tumor types are associated with different clinical syndromes. Heart valve damage has traditionally been linked only to serotonin-secreting tumors. This case expands the spectrum of neuroendocrine tumors that may affect the heart, which could influence screening protocols and diagnostic workups for patients with unexplained valvular disease.
What This Study Doesn't Tell Us
As a single case report, this cannot establish a causal relationship between VIPoma and carcinoid heart disease. It is unclear whether the cardiac findings were directly caused by VIP secretion or by other co-secreted substances. No mechanism is proposed for how VIP might cause valvular changes.
Questions This Raises
- ?Could VIP itself directly damage heart valves, or is the damage mediated by other substances co-secreted by the tumor?
- ?Should patients diagnosed with VIPoma routinely undergo echocardiographic screening for cardiac involvement?
- ?How many VIPoma patients have undetected subclinical valve disease that has simply never been looked for?
Trust & Context
- Key Stat:
- 0.05%–2% Incidence of VIPoma among neuroendocrine tumors — making this an exceptionally rare tumor type now linked to heart valve disease
- Evidence Grade:
- This is a single case report, which provides the lowest level of clinical evidence. While it raises an interesting and potentially important observation, it cannot establish causation or generalizability.
- Study Age:
- Published in 2024, this is a recent case report documenting a novel clinical observation that has not yet been corroborated by larger studies.
- Original Title:
- Carcinoid heart findings in vasoactive intestinal peptide-secreting tumour.
- Published In:
- BMJ case reports, 17(11) (2024)
- Authors:
- Joshi, Mugdha, Aldea, Daniel, Ngo, Peter, Shah, Sonia
- Database ID:
- RPEP-08499
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
What is a VIPoma and how is it different from a typical carcinoid tumor?
A VIPoma is a rare neuroendocrine tumor that secretes vasoactive intestinal peptide (VIP), causing watery diarrhea, flushing, and low potassium. Unlike classical carcinoid tumors that release serotonin, VIPomas were not previously thought to cause heart valve damage.
What is carcinoid heart disease?
Carcinoid heart disease occurs when chemicals released by neuroendocrine tumors damage the heart's valves, particularly the tricuspid valve on the right side of the heart. It causes the valve to thicken and malfunction, leading to regurgitation (leaking) and stenosis (narrowing).
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08499APA
Joshi, Mugdha; Aldea, Daniel; Ngo, Peter; Shah, Sonia. (2024). Carcinoid heart findings in vasoactive intestinal peptide-secreting tumour.. BMJ case reports, 17(11). https://doi.org/10.1136/bcr-2024-262229
MLA
Joshi, Mugdha, et al. "Carcinoid heart findings in vasoactive intestinal peptide-secreting tumour.." BMJ case reports, 2024. https://doi.org/10.1136/bcr-2024-262229
RethinkPeptides
RethinkPeptides Research Database. "Carcinoid heart findings in vasoactive intestinal peptide-se..." RPEP-08499. Retrieved from https://rethinkpeptides.com/research/joshi-2024-carcinoid-heart-findings-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.